correlation between expression of sil tal1 fusion gene and deletion of 6q in t cell acute lymphoblastic leukemia

• DOI: 10.7534/j.issn.1009-2137.2014.06.002
• Publication Date: 2014-12-01
• Authors: Haiping Dai; Qian Wang; Suning Chen; Nana Ping; Chunxiao Wu; Jinlan Pan; Huiying Qiu; Lili Wu; Jiannong Cen
• Keywords: Comparative Genomic Hybridization; Oncogene Proteins, Fusion; Reverse Transcriptase Polymerase Chain Reaction; Humans; Leukemia-Lymphoma, Adult T-Cell; Chromosomes, Human, Pair 6; Chromosome Deletion; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

The present study was designed to investigate the prevalence and clinical significance of SIL-TAL1 rearrangements in T-cell acute lymphoblastic leukemia (T-ALL). The incidence of SIL-TAL1 rearrangements was analyzed by nest real-time quantitative polymerase chain reaction (RT-PCR) in 68 patients with T-ALL. Karyotypic analysis was performed by conventional R-banding assay and array-based comparative genomic hybridization (array-CGH). The results showed that SIL-TAL1 rearrangements were identified in 10/26 (38.5%) pediatric and 2/42 (4.8%) adult T-ALL cases, which indicate a pediatric preference for SIL-TAL1 rearrangements in T-ALL. Two different transcripts were detected in 6/12(50%) T-ALL samples. Abnormal karyotypes were detected in 6 out of 11 cases (54.5%) and a deletion of the long arm of chromosome 6 was observed in 4 cases. Array-CGH results of 2 T-ALL cases with SIL-TAL1 rearrangement revealed that this fusion gene was resulted from a cryptic deletion of 1p32, and the overlap region of 6q deletion was 6q14.1-16.3. These cases with SIL-TAL1 fusion had a higher white blood cell (WBC) count and higher serum levels of lactate dehydrogenase (LDH) than cases without SIL-TAL1 fusion. It is concluded that SIL-TAL1 rearrangements are associated with loss of heterozygosity of chromosomal 6q, and SIL-TAL1-positive patients are younger than SIL-TAL1-negative patients. In contrast to the cases without SIL-TAL1 fusion, there are many adverse prognostic factors in the cases with SIL-TAL1 fusion, such as higher WBC count and higher LDH levels.